Literature DB >> 12825167

Noroviruses bind to human ABO, Lewis, and secretor histo-blood group antigens: identification of 4 distinct strain-specific patterns.

Pengwei Huang1, Tibor Farkas, Séverine Marionneau, Weiming Zhong, Nathalie Ruvoën-Clouet, Ardythe L Morrow, Mekibib Altaye, Larry K Pickering, David S Newburg, Jacques LePendu, Xi Jiang.   

Abstract

We characterized the binding of 8 Noroviruses (NORs) to histo-blood group antigens (HBGAs) in human saliva using recombinant NOR (rNOR) capsid proteins. Among the 8 rNORs tested, 6 formed viruslike particles (VLPs) when the capsid proteins were expressed in insect cells, all of which revealed variable binding activities with saliva; the remaining 2 rNORs did not form VLPs, and the proteins did not bind, or bound weakly, to saliva. Four distinct binding patterns were associated with different histo-blood types, defined by Lewis, secretor, and ABO types. Three patterns (VA387, NV, and MOH) recognized secretors, and 1 pattern (VA207) recognized Lewis-positive nonsecretors. The 3 secretor-recognizing patterns were defined as A/B (MOH), A/O (NV), and A/B/O (VA387) binders. Oligosaccharides containing the Lewis and ABH antigenic epitopes were involved in binding. Our findings suggest that different strains of NORs may recognize different human HBGAs on intestinal epithelial cells as receptors for infection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12825167     DOI: 10.1086/375742

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  176 in total

1.  Affinities of human histo-blood group antigens for norovirus capsid protein complexes.

Authors:  Ling Han; Elena N Kitova; Ming Tan; Xi Jiang; Benjamin Pluvinage; Alisdair B Boraston; John S Klassen
Journal:  Glycobiology       Date:  2014-10-01       Impact factor: 4.313

Review 2.  Role of histo-blood group antigens in primate enteric calicivirus infections.

Authors:  Karol Sestak
Journal:  World J Virol       Date:  2014-08-12

3.  Norovirus P particle, a novel platform for vaccine development and antibody production.

Authors:  Ming Tan; Pengwei Huang; Ming Xia; Ping-An Fang; Weiming Zhong; Monica McNeal; Chao Wei; Wen Jiang; Xi Jiang
Journal:  J Virol       Date:  2010-11-10       Impact factor: 5.103

4.  A candidate dual vaccine against influenza and noroviruses.

Authors:  Ming Xia; Ming Tan; Chao Wei; Weiming Zhong; Leyi Wang; Monica McNeal; Xi Jiang
Journal:  Vaccine       Date:  2011-08-11       Impact factor: 3.641

5.  Structural Evolution of the Emerging 2014-2015 GII.17 Noroviruses.

Authors:  Bishal Kumar Singh; Anna Koromyslova; Lisa Hefele; Clara Gürth; Grant S Hansman
Journal:  J Virol       Date:  2015-12-23       Impact factor: 5.103

6.  The carbohydrate moiety and high molecular weight carrier of histo-blood group antigens are both required for norovirus-receptor recognition.

Authors:  Pengwei Huang; Ardythe L Morrow; Xi Jiang
Journal:  Glycoconj J       Date:  2009-11       Impact factor: 2.916

7.  Identifying carbohydrate ligands of a norovirus P particle using a catch and release electrospray ionization mass spectrometry assay.

Authors:  Ling Han; Elena N Kitova; Ming Tan; Xi Jiang; John S Klassen
Journal:  J Am Soc Mass Spectrom       Date:  2013-10-05       Impact factor: 3.109

8.  Heterotypic humoral and cellular immune responses following Norwalk virus infection.

Authors:  Lisa C Lindesmith; Eric Donaldson; Juan Leon; Christine L Moe; Jeffrey A Frelinger; Robert E Johnston; David J Weber; Ralph S Baric
Journal:  J Virol       Date:  2009-12-09       Impact factor: 5.103

9.  Herd immunity to GII.4 noroviruses is supported by outbreak patient sera.

Authors:  Jennifer L Cannon; Lisa C Lindesmith; Eric F Donaldson; Lauryn Saxe; Ralph S Baric; Jan Vinjé
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

10.  Polyvalent complexes for vaccine development.

Authors:  Leyi Wang; Pengwei Huang; Hao Fang; Ming Xia; Weiming Zhong; Monica M McNeal; Xi Jiang; Ming Tan
Journal:  Biomaterials       Date:  2013-03-15       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.